Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Howard Hochster

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
The Oncologist|July 2, 2026
Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3Apostolia Maria Tsimberidou, Claire Verschraegen, Darren Sigal, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyHoward Hochster, Edie Weller, Randy D Gascoyne, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
Clinical Colorectal Cancer|December 17, 2005
Phase I/II dose-escalation study of pemetrexed plus irinotecan in patients with advanced colorectal cancerHoward Hochster, Erika Kettner, Hendrik Kroning, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancerDeepu Mirchandani, Howard Hochster, Anne Hamilton, et al.
American Journal of Clinical Oncology|September 10, 2009
Phase II study of paclitaxel plus the protein kinase C inhibitor bryostatin-1 in advanced pancreatic carcinomaAnthony P Lam, Joseph A Sparano, Vincent Vinciguerra, et al.
The Oncologist|July 2, 2026
Phase 2 Dose Expansion Trial of OBI-3424, a DNA-Alkylating Prodrug, in Patients with Advanced Solid Tumors Expressing AKR1C3Apostolia Maria Tsimberidou, Claire Verschraegen, Darren Sigal, et al.
Anti-Cancer Drugs|October 24, 2002
Phase I and pharmacologic study of i.p. 9-aminocamptothecin given as six fractions over 14 daysFranco M Muggia, Leonard Liebes, Maitreyee Hazarika, et al.
Anti-Cancer Drugs|April 13, 2004
A phase I and pharmacokinetic study of docetaxel combined with Doxil (pegylated liposomal doxorubicin) without and with granulocyte colony stimulating factorAnna C Pavlick, Catherine Chodkiewicz, Leonard Liebes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2004
Biweekly 72-hour 9-aminocamptothecin infusion as second-line therapy for ovarian carcinoma: phase II study of the New York Gynecologic Oncology Group and the Eastern Cooperative Oncology GroupHoward Hochster, Elizabeth R Plimack, Carolyn D Runowicz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 4, 2009
Maintenance rituximab after cyclophosphamide, vincristine, and prednisone prolongs progression-free survival in advanced indolent lymphoma: results of the randomized phase III ECOG1496 StudyHoward Hochster, Edie Weller, Randy D Gascoyne, et al.
Anti-Cancer Drugs|April 8, 2003
Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignanciesMissak Haigentz, Mimi Kim, Joan Sorich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2004
Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumorsSridhar Mani, Hayley McDaid, Anne Hamilton, et al.
Pageof 6